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Abstract
Objectives—To evaluate survival and predictors of mortality after cancer diagnosis among HIV-
infected persons receiving combination antiretroviral therapy (cART).
Design—Multisite cohort study.
Methods—We examined all-cause mortality among HIV-infected patients treated with cART in 
routine care at eight US sites and diagnosed with cancer between 1996 and 2009, and predictors of 
mortality using Cox proportional hazards regression models. Non-AIDS-defining cancers 
(NADCs) were classified as related and unrelated to viral coinfections.
Results—Out of 20 677 persons in the Centers for AIDS Research Network of Integrated 
Clinical Systems cohort, 650 cART-treated individuals developed invasive cancer. Of these, 305 
died during 1480 person-years of follow-up; crude mortality rate was 20.6 per 100 person-years 
[95% confidence interval (CI) 18.4, 23.1] and overall 2-year survival was 58% (95% CI 54, 62). 
Highest mortality was seen in primary central nervous system non-Hodgkin’s lymphoma, liver, 
and lung cancer with rates of 90.6, 84.3, and 68.1 per 100 person-years, respectively. Adjusted 
hazard of death was higher among those who were older and had stage IV cancer. Adjusted hazard 
of death was lower among those with higher CD4 cell counts at cancer diagnosis, who achieved 
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HIV-RNA suppression (≤400 copies/ml) on cART, received any cancer treatment, and had AIDS-
defining cancer or infection-related NADCs compared to infection-unrelated NADCs.
Conclusion—Independent predictors of mortality after cancer diagnosis among HIV-infected 
persons include poor immune status, failure to suppress HIV-RNA on cART, cancer stage, and 
lack of cancer treatment. Modification of these factors with improved strategies for the prevention 
and treatment of HIV and HIV-associated malignancies are needed.
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Introduction
The widespread use of combination antiretroviral therapy (cART) has led to dramatic 
reductions in morbidity and mortality from AIDS-related conditions for individuals infected 
with HIV [1,2]. However, several studies have reported an increased incidence of non-
AIDS-defining cancers (NADCs) [3–14], particularly those related to oncogenic viral 
coinfections, such as human papilloma-virus (HPV), Epstein–Barr virus (EBV), and 
hepatitis B or C virus (HBV or HCV) [8,15,16], among individuals with HIV-infection 
compared with the general population.
Trends in relative incidence rates of AIDS-defining cancers (ADCs) and NADCs have been 
well characterized [8,15–19], but little is known about survival after a diagnosis of cancer in 
the setting of HIV infection. Previous studies have been limited to examining individuals 
with AIDS in the pre-cART era or have lacked information regarding important risk factors 
[20–22]. We studied a large cohort of HIV-infected individuals engaged in routine care at 
eight clinical sites across the United States to define risk factors and mortality rates after a 
diagnosis of cancer in the modern cART era.
Methods
Study population
The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) 
was initiated in September 2006 to develop a comprehensive and standardized clinical data 
repository from point-of-care electronic medical record systems to support population-based 
HIV research [23]. The CNICS cohort includes over 20 000 HIV-infected adults (at least 18 
years of age) engaged in clinical care from 1 January 1995 to the present at eight CFAR 
sites. The frequency of follow-up averages every 3 months, however, patients can be seen 
more or less often depending on clinical care. CNICS is a dynamic cohort with 
approximately 1400 new patients enrolling and 10% of existing patients leaving care each 
year [23]. Institutional review boards at each University approved study protocols.
We examined all individuals in the CNICS cohort who were treated with cART for at least 6 
months and had a diagnosis of cancer between 1 January 1996 and 1 July 2009. Follow-up 
was administratively censored at 7 years to ensure adequate numbers of patients at risk for 
mortality.
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Upon entry into the CNICS cohort, standardized demographic and historical information, 
including prior diagnoses and antiretroviral treatment, are collected. Once enrolled in the 
cohort, data are prospectively captured at outpatient and inpatient encounters at the site 
medical center and include medications, laboratory test results, and AIDS-defining and non-
AIDS-defining conditions diagnosed by the treating provider and verified by medical record 
review (www.cnics.net). The following variables were included in this analysis: 
demographics (i.e., year of birth, sex, race/ethnicity), alcohol and tobacco exposure, 
intravenous drug use (IDU) as a risk factor for HIV transmission, HBV and HCV viral 
coinfection, AIDS-defining diagnoses, cART, CD4 cell counts, and plasma HIV-RNA 
levels. HCV infection was defined by positive HCV antibody or HCV-RNA testing prior to 
cancer diagnosis. HBV infection was defined by positive HBV surface antigen or HBV-
DNA testing prior to cancer diagnosis. CD4 cell count and HIV-RNA values at the time of 
cancer diagnosis were the values closest to the diagnosis date within a window of 9 months 
before and 3 months after cancer diagnosis. HIV-RNA suppression was defined as any HIV-
RNA level less than or equal to 400 copies/ml after cART initiation and before cancer 
diagnosis. Tobacco exposure and alcohol abuse were determined at the clinical assessment 
closest to cancer diagnosis to be current, past, or never. If there were no clinical records 
documenting alcohol or tobacco assessments prior to the cancer diagnosis or for 6 months 
after, the patient was classified as never exposed. Alcohol exposure was defined as abuse if 
qualitative assessments described ‘abuse’, ‘daily’, ‘dependence’, or ‘binge’ and if 
quantitative alcohol exposure was greater or equal to three drinks daily or 10 drinks per 
week.
Cancer verification
At each CNICS site, incident diagnoses of invasive cancer were reviewed using a 
standardized protocol to confirm the diagnosis and collect detailed information regarding 
cancer type, histology, grade, staging, and treatment from the medical record. Every CNICS 
site used the same protocol for cancer review and data collection. Cancer types were 
classified according to a predefined grouping based on location (i.e., anal, breast, cervix, and 
lung) and/or histopathologic reports (i.e., Kaposi’s sarcoma, lymphoma, and leukemia), 
nonmelanoma skin cancers were not included. Histology, grade, tumor nodes and metastasis 
and summary staging were obtained from information provided in pathology reports and 
clinician notes. If a patient had more than one cancer diagnosis, we analyzed only the first 
cancer observed. Treatment for cancer was defined as having received at least one treatment 
modality regardless of timing or completion of therapy categorized as surgery, 
chemotherapy, radiation, biologic, or none. Biopsy results confirmed 89% of non-Kaposi’s 
sarcoma cancers; the remaining cancers were diagnosed on the basis of clinical, 
radiographic, or historical information. Kaposi’s sarcoma was staged as mucocutaneous or 
visceral on the basis of AIDS Clinical Trials Group classification tumor status. Cancers 
qualitatively described as ‘metastatic’, ‘widespread’, or ‘disseminated’ were defined as stage 
IV. Visceral Kaposi’s sarcoma and primary central nervous system (CNS) non-Hodgkin’s 
lymphoma (NHL) were classified as ‘stage IV equivalent’ and mucocutaneous Kaposi’s 
sarcoma was classified as ‘not stage IV equivalent’. Cancer stage was categorized as 
Achenbach et al. Page 3













missing/unknown if staging information was not available after careful review of medical 
records.
To address the lack of complete data on cancer staging, we imputed missing ‘stage IV 
equivalent’ information as per the methods described below for the final multivariable 
analysis of all cancer cases. To examine the validity of this approach, we performed two 
prespecified subset analyses in which stage of cancer was known for all cases. The first 
subset analysis examined cancers using the I–IV summary staging classification (excluding 
Kaposi’s sarcoma, leukemia, multiple myeloma, primary CNS NHL, and primary brain). In 
this subset, we ran the same multivariable analyses conducted for the full cohort of cancer 
cases with the variable ‘stage IV’ or ‘not stage IV’. For the second subset analysis, we 
performed the same multivariable analysis with the addition of cases categorized as ‘stage 
IV equivalent’ or ‘not stage IV equivalent’.
ADCs included cervical, Kaposi’s sarcoma, and NHL according to the 1993 Centers for 
Disease Control and Prevention criteria [24]. NADCs were classified into those related to 
viral coinfections (HPV, EBV, and viral hepatitis) and those unrelated to viral coinfection. 
Infection-related NADCs included squamous cell anal, squamous cell oral cavity/pharynx, 
Hodgkin’s lymphoma, liver with viral hepatitis, vagina/vulva, and penis [16]. Infection-
unrelated NADCs included nonsquamous cell anal, biliary, bladder/urinary, primary brain, 
breast, colorectal, esophagus, nonsquamous cell oral cavity/pharynx, other head and neck, 
ovary, other (type unspecified or unknown), pancreas, kidney, leukemia, liver without viral 
hepatitis, lung, multiple myeloma, melanoma, peritoneum/retroperitoneum, prostate, small 
intestine, soft tissue, stomach, testicular, thyroid, trachea/pleura, and uterus.
Mortality ascertainment
Death data were obtained from clinic sources and confirmed by the National Death Index. In 
addition, the National Death Index was searched quarterly for all CNICS participants who 
were not known to be alive. We examined rates and predictors of all-cause mortality.
Statistical analysis
Mortality rates were calculated as number of deaths per 100 person-years of follow-up time. 
The complement of Kaplan–Meier survival curves were used to display the time from cancer 
diagnosis to death [25], as well as to estimate 2-year survival. We used Cox proportional 
hazards regression models to examine predictors of mortality [26]. Factors included in 
multivariable models were type of cancer (categorized as ADC, infection-related NADC, 
and infection-unrelated NADC), age, race/ethnicity, sex, viral hepatitis coinfection, current 
and past tobacco exposure, current and past alcohol abuse, nadir CD4 cell count, CD4 cell 
count at cancer diagnosis, pre-cART HIV-RNA level, HIV-RNA suppression on cART, 
noncancer AIDS-defining diagnosis, cancer stage, cancer treatment, and year of cancer 
diagnosis. The assumption that continuous predictors (i.e., age at cancer diagnosis, CD4 cell 
count, and HIV-RNA) had a log-linear association with the mortality hazard was explored 
and when violated the continuous predictor was categorized to reflect the nonlog-linear 
association. The proportional hazards assumption was explored graphically by plotting the 
log of the cumulative hazard by time.
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We imputed the median or modal value for infrequently missing variables (see Table 1, 
footnote b). In the final multivariable model, for cases missing ‘stage IV equivalent’ 
information (see Table 4, footnote b), we imputed missing values 25 times using a Markov 
chain Monte Carlo algorithm as implemented in the SAS (SAS Institute Inc., Cary, North 
Carolina, USA) procedure multiple imputation [27,28]. The first 1000 Monte Carlo draws 
were discarded to allow for a burn-in period, and the subsequent 5000 draws were used to 
summarize the joint posterior density. Imputations were based on information from all 
variables in Tables 1 and 4, including the occurrence and timing of deaths. We estimated 
summary hazard ratios as the antilog of the average of the 25 log hazard ratios. We 
estimated the variance of the hazard ratios by Rubin’s canonical imputation variance 
formula [27].
Results
Among a total of 20 677 HIV-infected persons enrolled in the CNICS cohort, there were 
1454 incident cases of invasive cancer. Six hundred and fifty patients treated with cART had 
a subsequent diagnosis of cancer between 1996 and 2009 (Table 1). The median age at 
cancer diagnosis was 44 years, 52% of participants were white, 86% were men, 18% 
reported IDU as a risk factor for transmission of HIV-infection, 21% were coinfected with 
viral hepatitis, 38% were current smokers (24% former), and 15% currently abused alcohol 
(8% former). Prior to treatment with cART, participants had a median nadir CD4 cell counts 
of 45 cells/µl and a median HIV-RNA of 5.4 log10 copies/ml. The initial cART regimen was 
anchored with an unboosted protease inhibitor in 269 of 650 (41%) of patients, a ritonavir-
boosted protease inhibitor in 197 of 650 (30%), a nonnucleoside reverse transcriptase 
inhibitor (NNRTI) in 166 of 650 (26%), and three nucleoside reverse transcriptase inhibitors 
in 18 of 650 (3%). The median time on cART before a diagnosis of cancer was 3.2 years. At 
the time of cancer diagnosis, 92% of the patients were still on cART, which included 
regimens anchored with a boosted protease inhibitor in 362 of 595 (60%) of patients, a 
NNRTI in 158 of 595 (27%), an unboosted protease inhibitor in 57 of 595 (10%), and other 
medications in 18 of 595 (3%). At any time before cancer diagnosis, 551 of 650 (85%) of 
patients achieved HIV-RNA suppression to less than or equal to 400 copies/ml. At cancer 
diagnosis, the median CD4 cell count was 204 cells/µl and median HIV-RNA was 2.6 log10 
copies/ml.
Infection-unrelated NADCs comprised 34% of cancers, whereas infection-related NADCs 
were 17% of cancers and ADCs accounted for 49% of cancers. Overall, the most common 
incident cancers were Kaposi’s sarcoma (29%), NHL (21%), lung (9%), and anal (8%) 
(Table 2). Staging information was available for 256 of 427 (60%) of cancers that use the I–
IV summary staging classification (excluding cases of Kaposi’s sarcoma, leukemia, multiple 
myeloma, primary CNS NHL, and primary brain). Of the 256 cancers classified by summary 
stage, 20, 19, 15, and 46% were stage I, II, III, and IV, respectively. Among patients with 
staging information, stage IV disease was documented in 40 of 70 (57%) with NHL, 26 of 
42 (62%) with lung cancer, two of 32 (6%) with anal cancer, 19 of 30 (63%) with Hodgkin’s 
lymphoma, two of 10 (20%) with prostate cancer, four of 12 (33%) with liver cancer, two of 
nine (22%) with kidney cancer, one of four (25%) with breast cancer, three of six (50%) 
with colon cancer, zero of two (0%) with melanoma, and 20 of 55 (36%) with other cancer 
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types. In addition, when classifying visceral Kaposi’s sarcoma and primary CNS NHL as 
‘stage IV equivalent’, staging information was available for 73% of cancers (463 of 634, 
excluding 16 cases of leukemia, multiple myeloma, and primary brain cancer). The majority 
(237 of 463, 52%) of these cancers were classified as ‘stage IV equivalent.’
Among the 650 HIV-infected patients diagnosed with invasive cancer on cART, there were 
305 deaths during 1480 person-years of follow-up for a crude mortality rate of 20.6 per 100 
person-years [95% confidence interval (CI) 18.4, 23.1], and an overall 2-year survival of 
58% (95% CI 54, 62) (Table 3). The highest mortality rates were among those with primary 
CNS NHL, liver, and lung cancer with rates per 100 person-years of 90.6, 84.3, and 68.1, 
respectively. The adjusted hazard ratio for death was higher among those who were older 
and had ‘stage IV equivalent’ cancer (Table 4). The adjusted hazard ratio for death was 
lower among those who had higher CD4 cell counts at cancer diagnosis, achieved HIV-RNA 
suppression to less than or equal to 400 copies/ml, received cancer treatment, and had ADCs 
or infection-related NADCs compared with infection-unrelated NADCs (Table 4 and Fig. 1). 
In adjusted analyses of the subset of 256 patients with known cancer summary stage, we 
found similar associations between all-cause mortality and age (hazard ratio 1.26; 95% CI 
1.00; 1.60, P = 0.05), HIV-RNA suppression (hazard ratio 0.38; 95% CI 0.20, 0.71; P < 
0.01), noncancer AIDS diagnosis (hazard ratio 1.70; 95% CI 1.10, 2.63; P = 0.02), stage IV 
cancer (hazard ratio 2.88; 95% CI 1.89, 4.37; P < 0.01), cancer treatment (hazard ratio 0.41; 
95% CI 0.20, 0.84; P = 0.02), and infection-related NADCs (hazard ratio 0.36; 95% CI 0.19, 
0.68; P < 0.01). In additional adjusted analyses of the subset of 463 patients with known 
‘stage IV equivalent’ cancer staging, we also found similar associations between all-cause 
mortality and age (hazard ratio 1.47; 95% CI 1.22, 1.77; P < 0.01), HIV-RNA suppression 
(hazard ratio 0.28; 95% CI 0.18, 0.44; P < 0.01), noncancer AIDS diagnosis (hazard ratio 
1.41; 95% CI 1.00, 2.00; P = 0.05), stage IV cancer (hazard ratio 2.68; 95% CI 1.89, 3.80; P 
< 0.01), receiving cancer treatment (hazard ratio 0.49; 95% CI 0.31; 0.79, P < 0.01), ADCs 
(hazard ratio 0.55; 95% CI 0.35, 0.86; P < 0.01), and infection-related NADCs (hazard ratio 
0.43; 95% CI 0.23, 0.78; P < 0.01).
Discussion
Cancer has been an important cause of morbidity and mortality for individuals with HIV-
infection since the beginning of the epidemic. Indeed, we found that in a large cohort of over 
20 000 HIV-infected persons receiving care at eight major metropolitan areas across the 
United States, more than 3% of patients receiving antiretroviral therapy developed cancer. 
We identified known risk factors for mortality including older age, stage IV cancer at time 
of diagnosis, and lack of cancer treatment. We also found key factors associated with 
mortality that are specific to HIV-infected patients and have not been previously reported, 
including failure to suppress HIV-RNA, low CD4 cell count at cancer diagnosis, and cancers 
unrelated to a viral coinfection. A possible explanation for these findings would be that 
HIV-RNA reduction and immunologic recovery from cART led to suppression of viral 
coinfection replication and its effects on tumor pathogenesis or growth of these cancers. 
Alternatively, among HIV-infected patients, these cancers may be less aggressive or more 
responsive to cancer treatment compared with NADCs unrelated to viral coinfection. 
However, classifying cancers as related to viral coinfection may not be of central clinical 
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importance when studying outcomes such as mortality. For example, in Figure 1c, we 
observed a notable difference within infection-related NADCs in which mortality was 
considerably higher for those with liver cancer compared with anal cancer or Hodgkin’s 
lymphoma. These findings point to the need for further study of the epidemiology and 
pathophysiology of cancer progression and viral coinfections in HIV disease. Particularly, 
more information is needed regarding outcomes of individual types of cancer among HIV-
infected individuals.
We observed several important findings with regard to mortality rates for individual cancers. 
Consistent with reports from other HIV-infected populations, the highest mortality rates for 
NADCs were among patients with liver and lung cancer [20,22], accounting for nearly 50% 
of deaths after NADC. Two-year survival for patients with liver cancer in this study was 
only 12%. Previous studies of mortality after liver cancer comparing those with and without 
HIV-infection have been mixed [29,30]. Mortality after NHL is known to be worse for 
patients with HIV, although a recent study from Europe suggested improved survival with 
cART [31]. Our results were consistent with another recent study of survival after NHL that 
directly compared those with and without HIV-infection in the cART era [32] and found 
40% 2-year survival for patients with HIV and 70% for those without HIV. Our findings 
also suggest that HIV-infection may increase mortality for patients with kidney cancer, as 2-
year survival was only 58%. Considering immune-modulating therapies are often used for 
treatment of renal cell carcinoma, immune deficiency or dysregulation due to HIV infection 
could unfavorably alter the pathogenesis of this cancer. This finding has not been previously 
reported and requires further investigation.
Increased mortality observed among those with lower CD4 cell counts highlights the 
importance of timely HIV treatment. The majority of patients in this study had very low 
nadir CD4 cell counts prior to initiation of cART and were unable to adequately rebuild their 
immune system with treatment. This finding is consistent with several studies showing that 
severity of immune suppression at time of cART initiation is predictive of the ability of 
antiretroviral treatment to significantly increase CD4 cell count [33–36]. Ongoing 
inflammation and immunodeficiency in patients who initiate cART at lower CD4 cell counts 
increases the risk of developing comorbid conditions, as demonstrated by the prognostic 
value of CD4 cell count and other immunologic markers in patients treated with cART 
[34,37]. Our results emphasize the importance of prompt and effective treatment of HIV 
with cART to reduce mortality from AIDS and non-AIDS-defining comorbid conditions, 
such as cancer.
More than 50% of HIV-infected patients diagnosed with cancer in our cohort had advanced 
(stage IV) disease at the time of diagnosis. Additionally, at least 25% of patients received no 
cancer treatment. This is surprising, as individuals in this study were receiving cART in 
specialized HIV clinics and routinely engaged in care with quarterly monitoring on average. 
Although it is possible that HIV infection and associated immune system dysfunction 
accelerate the rate of cancer progression to advanced and untreatable states, our findings 
could be explained by poor cancer awareness, inadequate screening practices, or lack of 
prompt therapy. HIV-infected individuals may require novel cancer prevention and 
treatment strategies that incorporate key prognostic factors such as those found in our study, 
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including suppression of HIV-RNA, prevention of CD4 cell count decline, and cancer 
screening initiated at a younger age than in the general population. Further research is 
needed to define the optimal timing and modalities for cancer screening and treatment 
among HIV-infected populations.
This study has several limitations. First, associations presented here reflect observational 
evidence and, therefore, could have been influenced by unmeasured risk factors for death 
such as active substance abuse or other comorbid disease. Second, although the present work 
reflects a large study of mortality after cancer diagnosis, information regarding tobacco 
exposure, alcohol abuse, viral hepatitis coinfection, noncancer AIDS diagnoses, cancer 
stage, and cancer treatment were subject to imprecision and potential misclassification. 
Third, despite extensive medical record review, detailed cancer staging information was not 
available for 26% of cancer diagnoses, a key predictor of mortality. However, we used 
multiple imputations to account for missing staging information in the final adjusted model 
for the full cohort, and our results were consistent with multivariable analyses conducted on 
two subsets of patients with known cancer stage. Fourth, we did not account for changes 
over time for certain factors, such as CD4 cell count and cART, which will be the focus of 
subsequent analyses. Fifth, we did not have information on cause of death and were unable 
to provide direct comparisons of our findings with a matched population of patients without 
HIV infection. In the modern era of cART, patients with cancer and HIV infection have 
several competing risks for death that vary depending on individual cancer type. We were 
limited by a small number of cases of specific cancer types and aggregate findings may not 
accurately capture outcomes for less common cancers. Future research in this area will 
require multicenter cohorts with large numbers of individuals with specific cancer types and 
detailed information about cause of death.
Despite these limitations, this work has several strengths. First, this was a multicenter 
collaborative effort from a large and diverse population with cancer diagnoses rigorously 
verified to minimize misclassification. Second, the occurrence and timing of mortality was 
based on active and passive surveillance also leading to minimal misclassification. Third, 
distinct from previous studies, we were able to examine multiple risk factors for mortality 
among HIV-infected patients with cancer including CD4 cell count, HIV-RNA level, cancer 
stage, viral hepatitis coinfection, smoking, and alcohol exposure.
In conclusion, among individuals with cancer and HIV infection treated with cART, we 
observed independent effects on mortality of low CD4 cell count, lack of HIV-RNA 
suppression and cancer treatment, and cancers unrelated to infection. In addition, a large 
proportion of patients engaged in routine HIV care were diagnosed late with stage IV 
cancer. Our results support earlier initiation of cART and aggressive cancer screening and 
treatment practices to maintain immunologic function, obtain optimal virologic suppression, 
control viral coinfections, detect cancers at an early stage, and provide appropriate cancer 
therapies. These findings exemplify the dynamic nature of the HIV epidemic in the current 
era of cART and highlight the need for continued research on prevention, diagnosis, and 
treatment of non-AIDS-defining conditions, including cancer.
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Fig. 1. Cumulative mortality over time
(a) By summary cancer type. (b–d) By individual cancer types within the cancer summary 
categories. ADC, AIDS-defining cancer; CNS, central nervous system; IR NADC, infection-
related non-AIDS-defining cancer; IU NADC, infection-unrelated non-AIDS-defining 
cancer; KS, Kaposi’s sarcoma; NHL, non-Hodgkin’s lymphoma.
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Table 1
Characteristics of 650 HIV-infected adults treated with combination antiretroviral therapy in the Centers for 
AIDS Research Network of Integrated Clinical Systems cohort diagnosed with cancer between 1996 and 
2009.
Characteristics at cancer diagnosisa Survivors Deaths Overall
Total, n 345 305 650
Follow-up time (years) 2.8 (1.2, 5.0) 0.6 (0.2, 1.5) 1.4 (0.4, 3.7)
Age (years) 43 (38, 50) 46 (40, 54) 44 (39, 51)
White, n (%) 203 (59) 137 (45) 340 (52)
Male, n (%) 293 (85) 263 (86) 556 (86)
HBV/HCV infection, n (%) 60 (17) 74 (24) 134 (21)
IDU, n (%) 49 (14) 69 (23) 118 (18)
Smoking, n (%)b
  Never 133 (39) 117 (38) 250 (38)
  Former 83 (24) 70 (23) 153 (24)
  Current 127 (37) 118 (39) 245 (38)
Alcohol abuse, n (%)b
  Never 270 (78) 226 (74) 496 (76)
  Former 25 (7) 29 (10) 54 (8)
  Current 46 (13) 50 (16) 96 (15)
Noncancer AIDS diagnosis, n (%)c 149 (43) 177 (58) 326 (50)
Nadir CD4 cell counts (cells/µlb) 62 (11, 174) 30 (4, 106) 45 (7, 137)
Pre-cART HIV-RNA (log10 copies/mlb) 5.3 (4.8, 5.7) 5.5 (4.9, 5.8) 5.4 (4.8, 5.8)
Time on cART, years 2.7 (0.5, 6.4) 3.4 (1.3, 5.6) 3.2 (0.7, 6.2)
HIV-RNA suppression to ≤400 copies/ml 329 (95) 222 (73) 551 (85)
CD4 cell count at cancer (cells/µlb) 238 (95, 469) 154 (23, 308) 204 (55, 393)
HIV-RNA at cancer (log10 copies/mlb) 2.3 (1.4, 4.4) 3.1 (1.9, 4.8) 2.6 (1.4, 4.6)
cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, 
intravenous drug use; KS, Kaposi’s sarcoma; NHL, non-Hodgkin’s lymphoma.
a
Median (quartiles) unless noted otherwise.
b
% (n) missing observations: smoking < 1% (2); alcohol < 1% (4); nadir CD4 cell count < 1% (1); pre-cART HIV-RNA <1% (4); CD4 cell count 
at cancer = 7% (44); HIV-RNA at cancer = 8% (51).
c
A noncancer AIDS diagnosis included any CDC AIDS-defining illness with the exception of NHL, KS or cervical cancer at or before cancer 
diagnosis.
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Table 2
Characteristics of 650 incident cancer cases among HIV-infected adults treated with combination antiretroviral 
therapy in the Centers for AIDS Research Network of Integrated Clinical Systems cohort between 1996 and 
2009.
Characteristics at cancer diagnosisa Survivors Deaths Overall
Total, n 345 305 650
Median year of diagnosis (range) 6/05 (2/03; 2/07) 7/03 (5/01; 1/06) 6/04 (2/02; 9/06)
Cancer diagnosis n (%) n (%) n (%)
  KS 123 (36) 62 (20) 185 (29)
  Non-CNS NHL 43 (12) 71 (23) 114 (18)
  Lung 11 (3) 48 (16) 59 (9)
  Anal 40 (12) 15 (5) 55 (8)
  Hodgkin’s lymphoma 26 (7) 6 (2) 32 (5)
  Prostate 21 (6) 6 (2) 27 (4)
  CNS NHL 3 (1) 19 (6) 22 (3)
  Liver 3 (1) 19 (6) 22 (3)
  Kidney 6 (2) 13 (4) 19 (3)
  Melanoma 13 (4) 2 (1) 15 (2)
  Breast 8 (2) 3 (1) 11 (2)
  Colorectal 7 (2) 4 (1) 11 (2)
  Other cancersb 41 (12) 37 (13) 78 (12)
Summary cancer diagnosis
  Infection-unrelated NADCs 99 (29) 122 (40) 221 (34)
  ADCsc 169 (49) 152 (50) 321 (49)
  Infection-related NADCsd 77 (22) 31 (10) 108 (17)
Summary stage
  I 38 (11) 13 (4) 51 (8)
  II 27 (8) 21 (7) 48 (7)
  III 17 (5) 21 (7) 38 (6)
  IV 43 (12) 76 (25) 119 (19)
  Missing 86 (25) 85 (28) 171 (26)
  Not applicablee 134 (39) 89 (29) 223 (34)
‘Stage IV equivalent’, n (%)f 98 (39) 139 (66) 237 (52)
Biopsy confirmation, n (%)g 280 (81) 262 (86) 542 (83)
Cancer treatment, n (%)h 270 (78) 215 (71) 485 (75)
ADC, AIDS-defining cancer; CNS, central nervous system; KS, Kaposi’s sarcoma; NADC, non-AIDS-defining cancer; NHL, non-Hodgkin’s 
lymphoma.
a
Median (quartiles) unless noted otherwise.
b
Other cancers: cervical, biliary, bladder/urinary, primary brain, esophagus, oral cavity/pharynx, other head and neck, leukemia, multiple myeloma, 
other (not specified or unknown origin), ovary, pancreas, penis, peritoneum/retroperitoneum, small intestine, soft tissue, stomach, testicular, 
thyroid, trachea/pleura, uterus, and vagina/vulva.
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c
ADCs: cervical, KS, and NHL.
d
Infection-related NADCs: squamous cell anal, squamous cell oral cavity/pharynx, Hodgkin’s lymphoma, liver with viral hepatitis, vagina/vulva, 
and penis.
e
Cancers that do not use I–IV summary staging: KS, primary CNS NHL, leukemia, multiple myeloma, and primary brain.
f
Among 463 cases (251 survivors and 212 deaths) that could be classified as ‘stage IV equivalent’ (excluding 171 missing and 16 cases of 
leukemia, multiple myeloma, and primary brain). Summary stage IV, visceral KS and primary CNS NHL classified as ‘stage IV equivalent.’ 
Summary stages I to III and mucocutaneous KS was classified as ‘not stage IV equivalent;’.
g
Biopsy confirmation obtained for 415 of 465 (89%) non-KS cancer diagnoses and for 127 of 185 (69%) of KS diagnoses.
h
Cancer treatment information missing for 86 (13%) of patients: 39 (11%) survivors and 47 (15%) deaths.
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Table 4
Adjusted mortality rate ratios of 650 incident cancer cases among HIV-infected adults treated with 
combination antiretroviral therapy in the Centers for AIDS Research Network of Integrated Clinical Systems 
cohort between 1996 and 2009.
Adjusted hazard ratioa 95% confidence intervals P-value
Age, per decade 1.44 1.25, 1.66 <0.01
Nonwhite vs. white 1.24 0.97, 1.59 0.09
Male vs. female 1.05 0.73, 1.51 0.78
HBV/HCV infection 1.29 0.97, 1.70 0.08
Smoking
  Current vs. never 1.00 0.76, 1.32 0.99
  Past vs. never 0.77 0.56, 1.10 0.11
Alcohol abuse
  Current vs. never 0.96 0.70, 1.32 0.81
  Past vs. never 1.30 0.86, 1.95 0.22
Nadir CD4 cell count, per 100 cells/µl 0.99 0.85, 1.15 0.85
CD4 cell count at cancer, per 100 cells/µl 0.90 0.83, 0.98 0.01
HIV-RNA suppression to ≤400 copies/ml 0.32 0.23, 0.44 <0.01
Pre-cART HIV-RNA, per log10 1.00 0.86, 1.15 0.97
Noncancer AIDS diagnosis 1.21 0.94, 1.55 0.14
‘Stage IV equivalent’b 2.30 1.69, 3.13 <0.01
Cancer treatment 0.55 0.39, 0.79 <0.01
Date of cancer diagnosis, per year 0.99 0.95, 1.03 0.57
Summary cancer diagnosis
  Infection-unrelated NADCs 1 Reference
  ADCsc 0.59 0.42, 0.81 <0.01
  Infection-related NADCsd 0.52 0.34, 0.78 <0.01
ADC, AIDS-defining cancer; cART, combination antiretroviral therapy; CNS, central nervous system; HBV, hepatitis B virus; HCV, hepatitis C 
virus; KS, Kaposi’s sarcoma; NADC, non-AIDS-defining cancer; NHL, non-Hodgkin’s lymphoma.
a
Adjusted for all variables in the table.
b
Summary stage IV, visceral KS, and primary CNS NHL classified as ‘stage IV equivalent.’ Summary stage I–III and mucocutaneous KS 
classified as ‘not stage IV equivalent.’ In the final model, ‘stage IV equivalent’ was imputed for 187 of 650 (29%) cases with missing information.
c
ADCs: cervical, KS, and NHL.
d
Infection-related NADCs: squamous cell anal, squamous cell oral cavity/pharynx, Hodgkin’s lymphoma, liver with viral hepatitis, vagina/vulva, 
and penis.
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